☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ☃ ❄ ⛄ ----- CONGÉ DES FÊTES 2016 ----- Veuillez noter qu'il n'y aura pas de suivi des dépôts des thèses et mémoires après le 22 décembre 2016. Retour aux délais réguliers de traitement dès le 5 janvier 2017.
Providing Genetic Testing Through the Private Sector: A View From Canada
Genetic testing technologies are rapidly moving from the research laboratory to the market place. Very little scholarship considers the implications of private genetic testing for a public health care system such as Canada’s. It is critical to consider how and if these tests should be marketed to, and purchased by, the public. It is also imperative to evaluate the extent to which genetic tests are or should be included in Canada’s public health care system, and the impact of allowing a two-tiered system for genetic testing. A series of threshold tests are presented as ways of clarifying whether a genetic test is morally appropriate, effective and safe, efﬁcient and appropriate for public funding and whether private purchase poses special problems and requires further regulation. These thresholds also identify the research questions around which professional, public and policy debate must be sustained: What is a morally acceptable goal for genetic services? What are the appropriate beneﬁts? What are the risks? When is it acceptable that services are not funded under health care? And how can the harms of private access be managed?
Publisher(s)ISUMA: Canadian Journal of Policy Research
Caulfield, T.; Burgess, M.M. & Williams-Jones, B.; with Baily, M-A.; Chadwick, R; Cho, M.; Deber, R.; Fleising, U.; Flood, C.; Friedman, J.; Lank, R.; Owen, T.; Sproule, J. 2001. “Providing Genetic Testing Through the Private Sector: A View From Canada” ISUMA: Canadian Journal of Policy Research 2(3): 72-81.